5 Results for "

Becotatug

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Becotatug" in MCE Product Catalog:

Cat. No.: HY-171265
Synonyms: MRG003
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
loading...
    loading...
Cat. No.: HY-P990049
CAS No.: 2648260-93-7
Synonyms: JMT-101; MRG003 Antibody

Target:  

EGFR

Research Areas:  

Cancer

Becotatug (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Studies related to Becotatug cover EGFR exon 20 insertion-mutated non-small cell lung cancer, recurrent or metastatic nasopharyngeal carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, and other conditions .
loading...
    loading...
Cat. No.: HY-P990049A

Target:  

EGFR

Research Areas:  

Cancer

Becotatug powder (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug powder specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug powder enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Studies related to Becotatug powder cover EGFR exon 20 insertion-mutated non-small cell lung cancer, recurrent or metastatic nasopharyngeal carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, and other conditions .
loading...
    loading...
Cat. No.: HY-185832
Research Areas:  

Cancer

SYS6010 is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR), which is formed by conjugating the anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) with the topoisomerase I inhibitor JS-1 (HY-178217) via a cleavable tetrapeptide linker. SYS6010 can be used in the research of advanced solid tumors such as non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-185833
Research Areas:  

Cancer

ADC Control Human IgG1-JSSW-001 is the isotype control for ADC SYS6010 (HY-185832). SYS6010 is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR), which is formed by conjugating the anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) with the topoisomerase I inhibitor JS-1 (HY-178217) via a cleavable tetrapeptide linker. SYS6010 can be used in the research of advanced solid tumors such as non-small cell lung cancer .
loading...
    loading...